12:00 AM
Oct 19, 2009
 |  BC Week In Review  |  Company News  |  Deals

Prosensa, GlaxoSmithKline deal

Prosensa granted GlaxoSmithKline exclusive, worldwide rights to develop and commercialize PRO051. The antisense oligoribonucleotide that induces exon 51 skipping on the dystrophin gene is expected to start Phase III testing early next year to treat Duchenne muscular dystrophy...

Read the full 186 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >